The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 multicenter, open-label, parallel cohort study to evaluate the efficacy, safety, and pharmacokinetic profile of ABN401 in patients with advanced solid tumors harboring c-MET dysregulation.
 
Xiuning Le
Consulting or Advisory Role - Abbvie; ABION; Allyst; ArriVent Biopharma; ArriVent Biopharma; AstraZeneca; Aviston; Bayer; Black Diamond Therapeutics; BlossomHill Therapeutics; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo/Lilly; EMD Serono; Hengrui Therapeutics; Janssen Oncology; Lilly; Merus; Novartis; PineTree; Regeneron; Spectrum Pharmaceuticals; Systimmune; Taiho Pharmaceutical
Research Funding - ArriVent Biopharma (Inst); Boehringer Ingelheim (Inst); EMD Serono (Inst); Janssen (Inst); Lilly (Inst); Regeneron (Inst); Teligene (Inst)
Travel, Accommodations, Expenses - EMD Serono; Johnson & Johnson/Janssen; Regeneron; Spectrum Pharmaceuticals
 
Hye Ryun Kim
Honoraria - AstraZeneca; MSD Oncology
Consulting or Advisory Role - AstraZeneca; BeiGene
Speakers' Bureau - ABL Bio; AstraZeneca; MSD Oncology; Ono Pharmaceutical; Roche/Genentech; Yuhan
Research Funding - AstraZeneca (Inst); Yuhan (Inst)
 
Dae Ho Lee
Honoraria - Abbvie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; ST Cube; Takeda; Yuhan
Consulting or Advisory Role - ABION; ST Cube
 
Se-Hoon Lee
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; Lilly; Merck Sharp & Dohme; Roche; Yuhan
Consulting or Advisory Role - Abion; AstraZeneca; BeiGene; BMS/Ono; Daiichi Sankyo; IMBdx; ImmuneOncia; Janssen; Lilly; Merck (German); Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Speakers' Bureau - Abion
Research Funding - AstraZeneca (Inst); Daiichi Sankyo; Lunit (Inst); Merck Sharp & Dohme (Inst)
 
Ki Hyeong Lee
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Johnson & Johnson/Janssen; Lilly; MSD; Pfizer; Takeda; Yuhan
Research Funding - Merck
(OPTIONAL) Uncompensated Relationships - Roche
 
Ji-Youn Han
Honoraria - AstraZeneca; Janssen; Merck; Novartis; Pfizer; Takeda; Yuhan
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Daiichi Sankyo/UCB Japan; Janssen; Merck; Novartis
Research Funding - Pfizer; Roche
 
Yu Jung Kim
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Bridge Biotherapeutics (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Gyeong-won Lee
No Relationships to Disclose
 
Young Saing Kim
Consulting or Advisory Role - Boryung; Chong Kun Dang Pharmaceutical; Yuhan
Research Funding - Merck KGaA
 
Jong Ran Kim
Employment - AbionBio
Leadership - AbionBio
Stock and Other Ownership Interests - AbionBio
Consulting or Advisory Role - ISU ABXIS; Neuramedy; Pin Therapeutics; Txinno